Development of transdermal drug delivery system of diltiazem hydrochloride for the treatment of hypertension

Development of transdermal system mainly focused on formulation and characterization of monolithic matrix type transdermal drug delivery system of diltiazem hydrochloride for the treatment of mild to moderate hypertension. In this study, seven formulations were prepared in different ratio of film forming polymers. Formulations TDDS1 to TDDS7 were composed of carboxy methyl cellulose, polyvinyl pyrrolidone and carbopol 934, 5% w/v in different ratio. Formulations also contained 5% (w/w) of diltiazem hydrochloride, 1% (v/w) of Polyethylene glycol 400 and 1% (w/w) of tween 60 (based on total polymer weight). Developed transdermal drug delivery system were characterized for various physicochemical properties such as thickness, moisture content, water vapor transmission, folding endurance, drug content and in vitro release study. Formulation TDDS7 was found to be better as compared to other formulations and it was selected as the developed formulation.